ADVFN - Advanced Financial Network.
HOME» NYSE » F » FRX Stock Price » FRX Stock News

Forest Labs Share News

 Forest Laboratories, Inc. Stock Price
FRX Stock Price
 Forest Laboratories, Inc. Stock Chart
FRX Stock Chart
 Forest Laboratories, Inc. Stock News
FRX Stock News
 Forest Laboratories, Inc. Company Information
FRX Company Information
 Forest Laboratories, Inc. Stock Trades
FRX Stock Trades

FDA: Forest Labs Lung Drug Effective For COPD; Raises Concerns

By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The Food and Drug Administration said a proposed lung drug that would be marketed by Forest Laboratories Inc. (FRX) to treat chronic obstructive pulmonary disease was effective, but raised concerns about potential heart problems. Forest is seeking FDA approval for aclidinium bromide, a long-acting inhaled drug developed for the treatment of COPD. Forest licensed the U.S. rights for the product from Almirall S.A. (ALM.MC). Aclidinium will be reviewed on Thursday by FDA's pulmonary allergy drugs advisory panel, which is made up of non-FDA medical experts. The FDA released a review of aclidinium on Tuesday in preparation for the meeting. The agency said three clinical studies of the drug showed it was effective at increasing airflow through the lungs compared to patients receiving a placebo, or inactive drug. FDA's safety review focused on cardiovascular risks because of concerns previously raised about other drugs in the same class. FDA said there was an "apparent imbalance" in cardiovascular deaths among patients treated with aclidinium compared to those not receiving the drug. There were four cardiovascular deaths among patients receiving a 400 microgram dose of the drug, but FDA said that event rate was lower than what is typically seen among COPD patients. "It is difficult to dismiss the apparent imbalance in cardiovascular deaths between the treatment groups, while at the same time, impossible to conclude that the data represent a true safety signal," FDA said. There is just one other long-acting drug for COPD, Spiriva, co-marketed by Boehringer Ingelheim GMBH and Pfizer Inc. (PFE), that is in the same class as aclidinium. Aclidinium, however, is designed to work in a different manner than Spiriva to keep airways open. In 2008, FDA started a safety review of Spiriva after receiving information from clinical studies that suggested the product might be associated with a higher stroke risk. But in 2010 the FDA cleared Spiriva of increasing stroke or heart problems. FDA will ask the panel to discuss whether clinical trials involving aclidinium were large enough and long enough to address safety questions. The panel will also be asked to vote on a series of questions about whether it thinks the product is safe and effective and whether it thinks the product should be approved. The FDA will make the final decision about whether to approve aclidinium but usually follows its panel recommendations. Forest, in a document posted to FDA's website Tuesday, said aclidinium "will provide an important additional...treatment option with demonstrated efficacy and safety." According to the National Institutes of Health, chronic obstructive pulmonary disease, marked by damaged lungs, is the fourth leading cause of death in the U.S., and is primarily caused by smoking. The disease causes the lungs' airways to become partly obstructed, making it difficult to breathe. --By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294; jennifer.corbett@dowjones.com

Stock News for Forest Labs (FRX)
DateTimeHeadline
06/24/201418:58:22Affiliated Managers Group to Join S&P 500
06/24/201409:51:44U.S. Hot Stocks: Hot Stocks to Watch
06/23/201418:21:28Forest Labs Posts Positive Results for Anxiety Disorder Drug
05/15/201418:00:08Third Point Adds New Stakes in American Airlines, Anheuser-Busch
05/14/201409:40:15Forest Labs' Saunders to Head Actavis After Deal
04/28/201417:23:16MARKET SNAPSHOT: U.S. Stocks End Choppy Trade Higher
04/28/201417:00:57MARKET SNAPSHOT: U.S. Stock Gains Fizzle As Internet Leaders...
04/28/201416:50:40MARKET SNAPSHOT: U.S. Stocks Rise Sharply On Deal News; Charter...
04/28/201416:49:07MARKET SNAPSHOT: U.S. Stocks Rise; Charter Rallies On Deal News
02/25/201407:20:12TPG 'Contemplating' Going Public
02/24/201417:01:35MARKET SNAPSHOT: Stocks Rally; S&P 500 Ends Right Below Record
02/24/201413:53:12MARKET SNAPSHOT: U.S. Stocks Rally As S&P 500 Hits Intraday Record
02/24/201405:47:09MARKET SNAPSHOT: U.S. Stock Market Is Starting To Ride A Tech...
02/18/201416:54:11MARKET SNAPSHOT: U.S. Stocks Edge Up; Nasdaq Gains For 8th Day...
02/18/201415:35:34MARKET SNAPSHOT: U.S. Stocks Churn; Coke Weighs On Dow, Nasdaq...
02/18/201411:32:36MARKET SNAPSHOT: U.S. Stock Gains Muted By Data; Coke Weighs...
02/18/201411:04:34MARKET SNAPSHOT: U.S. Stocks Edge Lower After Weak Data
02/18/201410:16:54MARKET SNAPSHOT: U.S. Stocks Edge Higher; Manufacturing Data...
01/21/201417:07:35MARKET SNAPSHOT: U.S. Stocks Close Higher; Earnings Misses Drag...
01/21/201412:37:10MARKET SNAPSHOT: U.S. Stocks Rise On China; J&J Drags On Dow

Forest Labs and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad